Cloning Vectors for the Production and Purification of Drug Delivery Vehicles Targeted to the CNS

University of Utah Technology Commercialization Office
posted on 01/16/2012

• request more info 
•   
•  LICENSE ONLINE

We have discovered modular cloning vectors used to produce drug delivery vehicles (drug, protein, or gene delivery) with simple purification based on the unique and customizable physiochemical characteristics of Elastin Like Polypeptides (ELP's).  The use of ELP's offer significantly simpler purification of drug delivery vehicles, comprised of cationic peptides & CNS targeting peptides, verses current methods of cationic peptide purification.  The modular cloning vectors allow for differing therapeutic payloads, routes of administration, and CNS specific targeting.

Features/Benefits

·        Drug Delivery Vehicle comprised of a cationic peptide and cell or tissue specific targeting peptide

·        Physiochemical characteristics of ELP's easily varied (MW, charge, hydrophobicity) to allow for simple purification of varied drug delivery vehicles

·        Scalable production for industrial applications (up to 180 mg/L in 24 hours)

·        Incorporation of diverse therapeutic payloads including small molecules, peptides, proteins, aptamers, plasmid DNA, miRNA, shRNA, & siRNA.

Technology Opportunity

A U.S. patent application (U.S. Serial No. 61/457,312) was filed with the U.S. Patent and Trademark Office.  The invention is available for licensing under either exclusive or non-exclusive terms.

Inventor

Dr. Darin Y. Furgeson, Dept. of Pharmaceutical Chemistry, University of Utah

Contact

James Thompson

University of Utah

Phone: (801)581-7792

Direct: (801)213-3564

james.thompson@tco.utah.edu